TBRA Tobira Therapeutics Inc.

TBRA SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Tobira Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information

The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Tobira Pharmaceuticals, Inc. (Nasdaq: TBRA) (“Tobira Pharmaceuticals” or the “Company”) relating to the proposed buyout of Tobira Pharmaceuticals by Allergan plc.

Under the terms of the agreement, Tobira Pharmaceuticals shareholders are anticipated to receive an upfront payment of $28.35 per share, in cash, and up to $49.84 per share in Contingent Value Rights (CVRs) that may be payable based on the successful completion of certain development, regulatory and commercial milestones, for each share of Tobira Pharmaceuticals common stock.

The firm’s investigation seeks to determine, among other things, whether the Company’s Board of Directors failed to satisfy their duties to shareholders, including whether the Board adequately pursued alternatives to the acquisition and whether the Board obtained the best price possible for the Company’s shares of common stock.

If you currently own common stock of Tobira Pharmaceuticals and believe that the proposed buyout price is too low, or you would like to learn more about the investigation being conducted by Brower Piven, please visit our website at http://www.browerpiven.com/currentinvestigations.html. You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.

EN
21/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Tobira Therapeutics Inc.

 PRESS RELEASE

Tobira Therapeutics Announces Late-Breaking Oral Presentation of CENTA...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ: TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced the acceptance of the company’s late breaking abstract as an oral presentation at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), being held in Boston, MA from November 11-15, 2016. The abstract entitled “Cenicrivi...

 PRESS RELEASE

Tobira Therapeutics Announces Presentations Related to Cenicriviroc’...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Tobira Therapeutics, Inc. (NASDAQ:TBRA), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for non-alcoholic steatohepatitis (NASH) and other liver diseases, today announced upcoming data presentations at the American Academy for the Study of Liver Diseases (AASLD) Annual Meeting (the Liver Meeting®), being held in Boston, MA from November 11-15, 2016. Poster Presentation Details Presentation Date/Time: Saturday, November 12, ...

 PRESS RELEASE

TBRA SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into T...

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Tobira Pharmaceuticals, Inc. (Nasdaq: TBRA) (“Tobira Pharmaceuticals” or the “Company”) relating to the proposed buyout of Tobira Pharmaceuticals by Allergan plc. Under the terms of the agreement, Tobira Pharmaceuticals shareholders are anticipated to receive an upfront payment of ...

 PRESS RELEASE

INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Into ...

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Tobira Therapeutics, Inc. (“Tobira”) (NASDAQ:TBRA) stock prior to September 20, 2016. You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Tobira to Allergan plc for $28.35 per share. The deal also includes up to $49.84 per share in Contingent Value Rights, payable upon the successful completion of certain milestone...

 PRESS RELEASE

TOBIRA PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A....

WILMINGTON, Del.--(BUSINESS WIRE)-- Rigrodsky & Long, P.A.: Do you own shares of Tobira Pharmaceuticals, Inc. (NASDAQ CM: TBRA)? Did you purchase any of your shares prior to September 20, 2016? Do you think the proposed buyout price is too low? Do you want to discuss your rights? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Tobira Pharmaceuticals, Inc. (“Tobira” or the “Company”) (...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch